Racial Disparities in the Treatment of Resectable Pancreatic Ductal Adenocarcinoma: A Propensity Score Matched Analysis

被引：0
|
作者：
Farah, Emile [1 ]
Abreu, Andres A. [1 ]
Rail, Benjamin [1 ]
Wang, Sam C. [1 ]
Porembka, Matthew R. [1 ]
Mansour, John C. [1 ]
Yopp, Adam C. [1 ]
Zeh, Herbert J., III [1 ]
Polanco, Patricio M. [1 ]
机构：
[1] Univ Texas Southwestern, Dallas, TX USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS | 2023年 / 237卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：S461 / S462
页数：2
相关论文
共 50 条
  • [21] Adjuvant Treatment of Surgically Resectable Pancreatic Ductal Adenocarcinoma
    Tesfaye, Anteneh A.
    Philip, Philip A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 54 - 63
  • [22] Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Kaufmann, Benedikt
    Hartmann, Daniel
    D'Haese, Jan G.
    Stupakov, Pavel
    Radenkovic, Dejan
    Gloor, Beat
    Friess, Helmut
    DIGESTIVE SURGERY, 2019, 36 (06) : 455 - 461
  • [23] Optimal Treatment for Octogenarians With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma
    Satoi, S.
    Yamamoto, T.
    Uchida, K.
    Fujii, T.
    Kin, T.
    Asano, T.
    Hanada, K.
    Itoi, T.
    Murakami, Y.
    Igarashi, H.
    Eguchi, H.
    Kuroki, T.
    Shimizu, Y.
    Tani, M.
    Tanno, S.
    Tsuji, Y.
    Hirooka, Y.
    Masamune, A.
    Mizumoto, K.
    Shimokawa, T.
    Yamaue, H.
    Okazaki, K.
    PANCREAS, 2019, 48 (10) : 1516 - 1517
  • [24] Folfirinox versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic adenocarcinoma: A propensity matched analysis.
    Dhir, Mashaal
    Zenati, Mazen S.
    Hamad, Ahmad
    Singhi, Aatur D.
    Bahary, Nathan
    Hogg, Melissa Ellen
    Zeh, Herbert
    Zureikat, Amer H.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [25] Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma
    Alvarez, R.
    Ales, I.
    Diaz, R.
    de Paredes, B. G.
    Hidalgo, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (10): : 1193 - 1198
  • [26] Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
    Ei, Shigenori
    Takahashi, Shinichiro
    Ogasawara, Toshihito
    Mashiko, Taro
    Masuoka, Yoshihito
    Nakagohri, Toshio
    GUT AND LIVER, 2023, 17 (05) : 698 - 710
  • [27] Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma
    R. Álvarez
    I. Alés
    R. Díaz
    B. G. de Paredes
    M. Hidalgo
    Clinical and Translational Oncology, 2017, 19 : 1193 - 1198
  • [28] Neoadjuvant Versus Adjuvant Radiation Therapy for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis
    Ma, Sung Jun
    Oladeru, Oluwadamilola T.
    Miccio, Joseph
    Stessin, Alexander
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E4 - E5
  • [29] Survival Benefit of Resection Surgery for Pancreatic Ductal Adenocarcinoma with Liver Metastases: A Propensity Score-Matched SEER Database Analysis
    Pausch, Thomas M.
    Liu, Xinchun
    Cui, Jiaqu
    Wei, Jishu
    Miao, Yi
    Heger, Ulrike
    Probst, Pascal
    Heap, Stephen
    Hackert, Thilo
    CANCERS, 2022, 14 (01)
  • [30] Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis
    Yuanchi Weng
    Yu Jiang
    Ningzhen Fu
    Jiabin Jin
    Yusheng Shi
    Zhen Huo
    Xiaxing Deng
    Chenghong Peng
    Baiyong Shen
    Surgical Endoscopy, 2021, 35 : 3437 - 3448
12345